|
Synonyms: BCA-1
Compound class:
Endogenous peptide in human, mouse or rat
Comment: CXCL13 is a C-X-C motif homeostatic chemokine that is selectively chemotactic for B cells belonging to both the B-1 and B-2 subsets. It exerts its biological effects via binding to the chemokine receptor CXCR5. CXCL13 expression can be regulated by the lymphotoxin β receptor (LTBR) pathway, and it contributes to ectopic tertiary lymphoid tissue development at sites of chronic inflammation in several autoimmune diseases, for example in the lacrimal and salivary glands of Sjögren's patients [4]. The CXCL13/LTBR axis is considered as a potential therapeutic target in conditions like Sjögren's syndrome. This is evidenced by the development of pharmaceutical agents that block LTBR activity being advanced to clinical trials (e.g. baminercept (BG9924) which is a soluble LTBR-IgG Fc fusion protein [3]).
Species: Human
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Barone F, Bombardieri M, Manzo A, Blades MC, Morgan PR, Challacombe SJ, Valesini G, Pitzalis C. (2005)
Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren's syndrome. Arthritis Rheum, 52 (6): 1773-84. [PMID:15934082] |
|
2. Barroso R, Martínez Muñoz L, Barrondo S, Vega B, Holgado BL, Lucas P, Baíllo A, Sallés J, Rodríguez-Frade JM, Mellado M. (2012)
EBI2 regulates CXCL13-mediated responses by heterodimerization with CXCR5. FASEB J, 26 (12): 4841-54. [PMID:22913878] |
|
3. Bienkowska J, Allaire N, Thai A, Goyal J, Plavina T, Nirula A, Weaver M, Newman C, Petri M, Beckman E et al.. (2014)
Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. PLoS ONE, 9 (11): e112545. [PMID:25405351] |
|
4. Fava RA, Kennedy SM, Wood SG, Bolstad AI, Bienkowska J, Papandile A, Kelly JA, Mavragani CP, Gatumu M, Skarstein K et al.. (2011)
Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome. Arthritis Res Ther, 13 (6): R182. [PMID:22044682] |
|
5. Salomonsson S, Jonsson MV, Skarstein K, Brokstad KA, Hjelmström P, Wahren-Herlenius M, Jonsson R. (2003)
Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. Arthritis Rheum, 48 (11): 3187-201. [PMID:14613282] |
|
6. Sáez de Guinoa J, Barrio L, Mellado M, Carrasco YR. (2011)
CXCL13/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics. Blood, 118 (6): 1560-9. [PMID:21659539] |
